Story
Apnimed Stock Climbs Over 10% as Wall Street Initiates Bullish Coverage

Shares of Apnimed Inc. (NASDAQ:APMD) jumped 10.3% on Tuesday after several Wall Street analysts initiated coverage on the biotechnology company with bullish outlooks. The positive ratings centered on the commercial potential of Apnimed's lead drug candidate for obstructive sleep apnea (OSA).
Wave of Positive Ratings
At least four investment firms began covering Apnimed, signaling growing investor interest in the company's pipeline. The new ratings and price targets include:
- Cantor Fitzgerald: Initiated with an Overweight rating and a $60 price target.
- BofA Securities: Initiated with a Buy rating and a $41 price target.
- LifeSci Capital: Initiated with an Outperform rating and a $50 price target.
- Evercore ISI: Initiated with an Outperform rating.
Cantor Fitzgerald analyst Josh Schimmer's price target, based on a discounted cash flow analysis, represents nearly double the stock's Tuesday trading price of around $32, according to the firm's note.
Focus on Sleep Apnea Drug Oxnimbi
AdThe analysts' optimism is focused on Oxnimbi, Apnimed's investigational oral treatment for obstructive sleep apnea. The drug is a combination pill of oxybutynin and atomoxetine designed to address the underlying cause of OSA, a condition where the upper airway collapses during sleep, leading to obstructed breathing.
According to Cantor Fitzgerald, Oxnimbi works by "increasing muscle tone during deep sleep," which prevents airway collapse. The therapy has a Prescription Drug User Fee Act (PDUFA) target action date with the FDA set for February 28, 2027.
Sizing the Market Opportunity
Analysts highlighted the significant unmet need in the OSA market. BofA Securities analyst Jason Gerberry pointed to a large initial opportunity among an estimated 10.5 million patients in the U.S. who have been diagnosed but remain untreated.
Gerberry's thesis rests on Oxnimbi's differentiated mechanism compared to existing treatments, positive Phase 3 data that showed significant reductions in breathing interruptions, and the large patient population. BofA Securities models potential peak U.S. sales of approximately $2 billion on a nominal basis and $1.7 billion on a risk-adjusted basis.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.